Equity Overview
Price & Market Data
Price: $2.77
Daily Change: +$0.503 / 18.14%
Daily Range: $2.15 - $2.84
Market Cap: $174,765,456
Daily Volume: 831,787
Performance Metrics
1 Week: 24.11%
1 Month: 52.75%
3 Months: 65.48%
6 Months: 164.8%
1 Year: 208.0%
YTD: -4.14%
Company Details
Employees: 131
Sector: Health technology
Industry: Biotechnology
Country:
Details
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT3789, a selective degrader of SMARCA2 protein for the treatment of advanced or metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion; PRT7732, a selective and orally bioavailable SMARCA2 degraders to treat advanced or metastatic solid tumors; and PRT2527, a cyclin-dependent kinase 9 inhibitor for the treatment of advanced solid tumors. The company's CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC, and MYB. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.